Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ERVEBO safely and effectively. See full prescribing information for ERVEBO. ERVEBO® (Ebola Zaire Vaccine, Live) injectable suspension, for intramuscular use Initial U.S. Approval: 2019
Medication labelWhy this: Advisory · dailymed-other
ERVEBO® is indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older. The duration of protection conferred by ERVEBO is unknown. ERVEBO does not protect against other species of Ebolavirus or Marburgvirus. Effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (IG), and/or blood or plasma transfusions is unknown.
- generic_name
- zaire ebolavirus (strain kikwit-95) envelope glycoprotein
- product_names
- ZAIRE EBOLAVIRUS (STRAIN KIKWIT-95) ENVELOPE GLYCOPROTEIN
- ndc
- 0006-4293, 0006-4293-01, 0006-4293-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en